Specialty Chemicals Patents: Top Companies & Filing Trends 2026
- Concentration at the top. The five leading assignees hold 41.4% of all 1,263 records in scope, and the leading ten hold 56.6% — a field where a handful of filers set the boundaries of the claim space.
- Filing has cooled from its 2020 peak. Volume ran from 45 records in 2021 down to 15 in 2024, a 67% decline over that span; 2025 and 2026 figures are still filling in as publication lags filing by roughly 18 months.
- Medicinal preparations dominate the class mix. A61K accounts for 27.4% of all 1,263 records, well ahead of detergents, condensation polymers and lubricants — each sitting in the 13-14% range.
Filing growth compares 2021 (45 records) with 2024 (15) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,263 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset draws on 1,263 published records filed against specialty and industrial chemical terms spanning reaction media, process streams, mass transfer, product selectivity, molecular structure and product formulation. It spans filings from 2015 through the 2026 cut-off, though the most recent two years are still incomplete because publication typically lags filing by roughly eighteen months. The scope favours formulation and process claims over pure composition-of-matter work, which is why medicinal preparations and cleaning compositions surface as the largest IPC subclasses rather than bulk commodity chemistry.
Reading the landscape by patent family rather than raw document count matters here: several of the most-cited records in this corpus are continuations of the same underlying polymer-blend disclosure, which inflates document counts without adding new claim territory. The concentration figures and class shares below are built on the full 1,263-record set so any share quoted always carries its denominator.
Filing trend and technology composition
Two views of the same 1,263-record set: how filing volume has moved year over year, and how those records distribute across IPC subclasses. Because a single record can carry several IPC codes, the class shares below sum to more than 100% of the record total — that is expected and is not a data error.
Filing volume peaked in 2020, then declined
Volume rose to a peak of 99 records in 2020, then fell from 45 in 2021 to 15 in 2024 — a 67% drop over three years. Treat 2025 and 2026 as undercounted rather than as evidence the field has gone quiet; the publication lag means recent filings simply have not surfaced yet.
Medicinal preparations lead a formulation-heavy mix
A61K (medicinal preparations) tops the class list at 27.4% of the 1,263 records, followed by detergents & cleaning compositions (13.7%), condensation polymers (13.5%) and lubricants (13.1%). Sterilising/disinfecting, cosmetics use, misc.-application materials and implants/prostheses each hold a smaller but non-trivial share, pointing to a field where formulation and delivery claims outnumber pure synthesis claims.
Shares are the percentage of the 1,263 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Specialty & Performance Chemicals Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about specialty & performance chemicals patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records and a representative filing
Method for selective production of biobased chemicals and biofuels from plant lignin
The filing describes a method of producing biobased chemicals, biofuels and lignin residues from lignin sources, including waste lignin, using chemical-induced processing, catalytic oxidative depolymerisation, and catalytic hydroprocessing (including catalytic hydrodeoxygenation and related reduction steps). It is framed around selectively steering the reaction outputs rather than a single fixed product.Filed by Vertichem Corporation; illustrates how process-route claims in this space are typically drafted around selectivity and conversion pathway rather than a single named end product.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5330768A | Controlled drug delivery using polymer/pluronic blends | 645 |
| 2 | US20050208095A1 | Polymer compositions and methods for their use | 391 |
| 3 | US20050175703A1 | Polymer compositions and methods for their use | 376 |
| 4 | US20050175665A1 | Polymer compositions and methods for their use | 352 |
| 5 | US20110268802A1 | Delivery particle | 337 |
| 6 | US6667048B1 | Emulsion vehicle for poorly soluble drugs | 327 |
| 7 | US6458373B1 | Emulsion vehicle for poorly soluble drugs | 305 |
| 8 | US20070299043A1 | Anti-scarring drug combinations and use thereof | 292 |
| 9 | US20050196421A1 | Polymer compositions and methods for their use | 252 |
| 10 | US20070208134A1 | Anti-scarring drug combinations and use thereof | 229 |
Citation counts reward older records that have had more time to accumulate citations within this searched corpus — read them as a signal of influence on the field, not as a ranking of current commercial importance. Several of the top entries are continuations of the same polymer/pluronic blend disclosure rather than independent inventions.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three findings from the dataset that should shape where a new filing gets aimed and how a freedom-to-operate search gets scoped.
The top of the field is crowded, not the whole field
Five assignees hold 41.4% of all 1,263 records and ten hold 56.6%. That leaves a long tail of single- and few-filing entrants working the remaining space, which is where a narrowly drafted claim is more likely to clear prior art untouched by the leaders.
Volume has fallen from its 2020 peak
Filing dropped from 45 records in 2021 to 15 in 2024, a 67% decline. Several of the leading assignees show zero filings in the latest tracked year, though this should be read alongside the publication lag rather than taken as a sign the technology is abandoned.
Formulation claims outnumber pure synthesis claims
Medicinal preparations (A61K) lead at 27.4%, with detergents, condensation polymers and lubricants each near 13-14%. High density in A61K signals that the delivery-and-formulation claim space is occupied; adjacent process-route claims may have more room.
Co-filing is concentrated among a small cluster
Only ten co-assignee pairs appear in the dataset, and the strongest pairs share filings in the 30s-40s range, all involving the same small group of individual co-inventors. This points to a tight collaborative core rather than broad cross-licensing across the field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to specialty & performance chemicals patent landscape, with the prior art for and against each one.
Who is filing, and who has slowed down
The ranked leaders account for a little over half of all activity in this corpus, but momentum has cooled across nearly all of them in the most recent tracked year — a useful cue that the current filing window favours new entrants over the incumbents that built the early portfolio.
A single filer holds a clear lead
The top-ranked assignee holds 178 records, well ahead of the fifth-place holder at 44 and tenth place at 34 — a steep drop-off that marks a genuine leader rather than a crowded tie at the top.
Leading filers show zero activity in the latest year
Multiple leading assignees, including the top-ranked filer, show no filings in the most recent tracked year. Given the roughly 18-month publication lag, this is as likely to reflect incomplete data as an actual pullback, but it does mean the newest activity in the field is not coming from the historical leaders.
Co-filing is rare and clustered
Only ten co-assignee pairs exist across the dataset, concentrated among a small group of individual co-inventors rather than corporate joint ventures. Most assignees in the ranking file independently.
| Assignee | Recent year | YoY |
|---|---|---|
| Procter & Gamble Co | 0 | -100% |
| ExxonMobil Technology & Engineering Co | 0 | — |
| ANGIOTECH INT AG (CH) | 0 | — |
| The Lubrizol Corp | 0 | — |
| Sasol Chemicals GmbH | 0 | — |
| TOLEIKIS PHILIP M | 0 | — |
| GRAVETT DAVID M | 0 | — |
| Sonus Pharmaceuticals Inc | 0 | — |
Where to take this analysis
The landscape narrows a broad search string down to a ranked set of assignees and classes. The next steps depend on whether the goal is freedom-to-operate, portfolio benchmarking, or scouting for a specific technical route.
Run a freedom-to-operate check on a specific claim
Take a candidate claim in one of the under-claimed branches — such as a lignin depolymerisation route or a process-selectivity mechanism — and check it against the most-cited records and the leading assignees' active families before drafting.
Open Eureka →Track the leaders that have gone quiet
Several top-ranked assignees show zero filings in the latest tracked year. Set up monitoring to catch the moment any of them resumes filing, since a returning incumbent changes the competitive picture fast.
Open Eureka →Map the co-filing cluster
The ten co-assignee pairs in this dataset point to a small, tightly connected inventor group. Understanding who they've worked with historically can flag likely future collaborators or licensing targets.
Open Eureka →Common questions about this landscape
The ranking in this dataset covers 100 companies, and it is concentrated rather than evenly spread: the top five assignees together hold 41.4% of all 1,263 records in scope, and the top ten hold 56.6%. The single leading assignee holds 178 records, well clear of the fifth-place holder at 44 and tenth place at 34. That gap between first and fifth place is a strong signal that one filer has built a materially larger portfolio than everyone else, so any competitive read of this space should treat that leader as a distinct category rather than grouping it with the rest of the top ten.
Filing volume peaked in 2020 at 99 records and then declined, falling from 45 records in 2021 to 15 in 2024 — a 67% drop over that three-year span. However, the two most recent years in any dataset like this are always understated because publication lags actual filing by roughly 18 months, so 2025 and 2026 figures should not be read as a continuation of the decline. The honest summary is that the field has cooled from its 2020 high, with the true current trajectory not yet visible in the data.
Medicinal preparations (IPC class A61K) lead with 27.4% of the 1,263 records in scope, ahead of detergents and cleaning compositions (13.7%), condensation polymers (13.5%) and lubricants (13.1%). Sterilising and disinfecting, cosmetics use, misc.-application materials, and implants and prostheses each account for smaller but still notable shares. Because a single record can carry more than one IPC class, these percentages add up to more than 100% of the record total, which is normal and not a data error.
The most-cited record in this corpus is a polymer/pluronic blend patent for controlled drug delivery, cited 645 times, with several related continuation filings from the same family also appearing among the most-cited records. High citation counts in a searched corpus like this tend to favour older filings simply because they have had more years to accumulate citations, so this should be read as a marker of historical influence on the field rather than a statement about current commercial relevance. A freedom-to-operate check should still examine the specific claims of that family directly rather than relying on the citation count alone.
The clearest signal of white space in this dataset is the gap between the dense formulation classes — A61K, C11D, C08G and C10M all sit in the 13-27% range — and the process-route work represented by filings like the lignin-to-biobased-chemicals patent, which sits in a comparatively less crowded area built around catalytic selectivity and conversion pathway rather than a single end-formulation. Branches built around mass-transfer-optimised reaction media, process-stream selectivity control, and catalytic hydrodeoxygenation process claims show lower filing density relative to the core formulation classes. A first claim in these areas should be anchored to a specific conversion mechanism or selectivity control point rather than a broad composition, since that is where the dense prior art has left the least coverage.
Research Specialty & Performance Chemicals Patent Landscape in depth with Eureka
Go past this page: query the whole specialty & performance chemicals patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.